|
|
Quest Diagnostics Inc (NYSE: DGX) |
|
Price: $151.2000
$-0.46 
-0.303%
|
| Day's High:
| $153.58
| Week Perf:
| -1.83 %
|
| Day's Low: |
$ 151.10 |
30 Day Perf: |
-0.95 % |
| Volume (M): |
760 |
52 Wk High: |
$ 165.32 |
| Volume (M$): |
$ 114,912 |
52 Wk Avg: |
$143.86 |
| Open: |
$151.55 |
52 Wk Low: |
$123.04 |
|
|
| Market Capitalization (Millions $) |
17,086 |
| Shares
Outstanding (Millions) |
113 |
| Employees |
48,000 |
| Revenues (TTM) (Millions $) |
9,539 |
| Net Income (TTM) (Millions $) |
890 |
| Cash Flow (TTM) (Millions $) |
621 |
| Capital Exp. (TTM) (Millions $) |
374 |
Quest Diagnostics Inc
Quest Diagnostics Inc.: Overview
Company Profile:
Quest Diagnostics Incorporated is the largest provider of diagnostic testing, information, and related services in the United States. Founded in 1967 and headquartered in Secaucus, New Jersey, Quest is dedicated to providing medical insights that enable healthcare professionals'such as physicians, hospitals, and managed care organizations'to enhance patient health decisions.
Services Provided:
Quest Diagnostics offers a wide array of diagnostic laboratory services. The company is recognized for its extensive national network, which includes numerous laboratories and patient service centers (PSCs). Key offerings include:
1. Diagnostic Testing:
- Quest provides comprehensive laboratory testing services including routine tests, esoteric testing, and specialized testing services such as gene-based assays and toxicology testing for drugs of abuse.
2. Anatomic Pathology Services:
- The company is a leading provider of anatomical pathology services, offering diagnostic test services that include histopathology and biopsies.
3. Clinical Trials:
- Quest supports drug development through laboratory tests and information services in clinical trials, leveraging its expertise in lab sciences to promote patient safety and efficacy assessments.
4. Interpretive Consultation:
- Quest offers professional consultation services with a large team of over 300 medical professionals, including board-certified pathologists and Ph.D.s, who provide interpretive guidance on complex test results to healthcare providers.
5. Information Technology Solutions:
- The company provides advanced IT solutions to healthcare organizations, allowing for improved practice management, patient care documentation, and streamlined workflows'all aimed at enhancing the overall efficiency of healthcare delivery.
Operational Footprint:
Quest Diagnostics operates a vast network, which includes over 2,200 patient service centers, more than 50 laboratory locations nationwide, and a workforce comprising tens of thousands of employees. This extensive infrastructure ensures broad access to testing services for both patients and healthcare providers.
Focus Areas:
- Esoteric Testing: Quest has established itself as a leading provider of esoteric tests, which are specialized tests not commonly performed in routine laboratories. These tests often play a crucial role in diagnosing complex conditions and guiding treatment plans.
- Genomic and Genetic Testing: The company is at the forefront of gene-based testing, including genetic screening and genomic profiling, which are instrumental in personalized medicine and targeted therapy.
- Substance Abuse Testing: Quest offers an array of services for testing drugs of abuse, contributing significantly to the monitoring and detection of substance use disorders across various demographics and sectors, including workplace wellness programs.
Partnerships and Affiliations:
Quest Diagnostics collaborates with healthcare providers, pharmaceutical and biotechnology companies, and research institutions to enhance Healthcare outcomes. The company actively engages in partnerships that facilitate clinical trials and new test development, ensuring it remains integral to evolving healthcare trends.
Regulatory Compliance:
As a key player in the healthcare sector, Quest Diagnostics adheres to stringent regulatory standards imposed by agencies such as the Clinical Laboratory Improvement Amendments (CLIA) and the College of American Pathologists (CAP). This commitment to compliance and quality assurance underpins its reputation and trust within the medical community.
Recent Developments and Innovations:
- In recent years, Quest has expanded its offerings to include more robust digital health solutions, augmenting traditional laboratory services with telehealth capabilities, patient-facing applications, and enhanced data analytics.
- The company has also emphasized the importance of corporate social responsibility, focusing on community health programs and addressing health disparities within underserved populations.
Through its innovative services and extensive capabilities, Quest Diagnostics continues to lead the diagnostic testing industry, enhancing patient care and supporting healthcare providers in delivering high-quality medical services.
Company Address: 500 Plaza Drive Secaucus, 7094 NJ
Company Phone Number: 520-2700 Stock Exchange / Ticker: NYSE DGX
|
|
|
Customers recorded net loss |
Customers recorded net loss |
|
|
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Quest Diagnostics Inc
nnBearish Analysis of Quest Diagnostics Inc.: Revenue Growth Fails to Bolster Declining Incomenn
In the fiscal reporting period ending June 30, 2024, Quest Diagnostics Inc. has found itself in a precarious position. Despite a revenue growth of 2.524%, the company reported a troubling income decline of 0.98% compared to the same reporting season a year earlier. With revenue reaching $2.40 billion and earnings per share (EPS) at $2.03, there are deep underlying concerns that suggest this growth may indicate more than just a slow fiscal moment?it may signal systemic weakness in the company's financial health.
# Disappointing Metrics
To begin with, it's crucial to highlight that the company?s revenue growth fell short of the broader Medical Laboratories industry, which reported a robust 3.66% increase relative to Q2 of 2023. This underperformance raises red flags about Quest Diagnostics? competitive positioning in an industry that is rapidly innovating and evolving. While a 2.524% increase in revenue might seem positive on the surface, in the context of the industry?s higher performance, it showcases Quest Diagnostics' inability to keep pace with its competitors.
|
| Quest Diagnostics Inc
The fiscal interval closing March 31, 2024, has brought some mixed results for Quest Diagnostics Inc, a leading provider of diagnostic information services. While the company saw a modest revenue rise of 1.502%, reaching $2.37 billion, its income experienced a contraction of -3.37% compared to the same quarter a year ago. Earnings per share (EPS) stood at $1.72 during this period.
One of the key highlights of Quest Diagnostics' performance in the fiscal interval was its focus on improving sales, leading to a net margin of 8.79%. However, the company's operating earnings fell by -1.64% to $300 million, resulting in a decrease in operating margin from 13.08% in the first quarter of 2023 to 12.68% in the current period. The bottom-line of $208.000 million in the fiscal interval marked a -4.15% decline from the corresponding period a year before when it was $217.000 million.
|
| Quest Diagnostics Inc
In the financial fourth quarter of 2023, Quest Diagnostics Inc (DGX) reported a decrease in revenue but managed to raise its earnings per share, showing positive growth in its income per share. Despite a decline in revenue by -1.929% to $2.29 billion year on year, income per share surged by 91.92% to $1.68 per share. This marks a decrease from the previous reporting period where profits fell from $1.96 per share and revenue decreased by -0.305% from $2.30 billion.
Net income also saw a significant increase in the financial fourth quarter of 2023, rising by 76.72% to $205.000 million from $116.000 million reported in the same quarter a year ago. Quest Diagnostics Inc also highlighted its improving profit margins, with net margin rising to 8.96% and operating margin edging up to 11.67%. Despite an increase in stockpiles to $190.0 million due to seasonal factors, they remain below the previous year's level of $192.0 million. Operating earnings also showed growth, rising by 97.78% to $267 million.
|
| Product Service News
Published Tue, Jan 9 2024 1:05 PM UTC
Quest Diagnostics and Ultima Collaborate to Revolutionize Oncology and Clinical Diagnostics with Next-Generation Sequencing TechnologyIn a groundbreaking partnership, Quest Diagnostics, the leading provider of diagnostic information services, and Ultima Genomics, the developer of an innovative ultra-high throughput sequencing architecture, have joined forces to accelerate th...
|
| Quest Diagnostics Inc
Quest Diagnostics Inc, one of the leading medical laboratories in the industry, reported a decline in its bottom-line and income per share for the July to September 30, 2023 interval. The bottom-line decreased by 9.68% to $1.96 per share compared to $2.17 per share in the same period a year ago, while income per share decreased by 4.39% from $2.05 per share in the previous reporting period.
These disappointing results were mirrored in the company's revenue, which decreased by 7.683% to $2.30 billion from $2.49 billion in the comparable reporting period last year. Sequentially, the revenue declined by 1.839% from $2.34 billion. It is important to note that this deterioration in revenue is in stark contrast to the overall trend in the Medical Laboratories industry, which experienced a top-line rise during the same period.
Furthermore, Quest Diagnostics Inc's earnings for the July to September 30, 2023 interval also suffered, falling by 14.13% to $237 million compared to $276 million in the corresponding period a year ago. This decline in earnings contributed to the decrease in profitability, with the operating margin decreasing to 14.9% and the net margin shrinking to 10.33%.
|
| Per Share |
Current |
| Earnings (TTM) |
7.42 $ |
| Revenues (TTM) |
84.42 $
|
| Cash Flow (TTM) |
5.5 $ |
| Cash |
6.76 $
|
| Book Value |
60.54 $
|
| Dividend (TTM) |
2.9 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
7.42 $
|
| Revenues (TTM) |
84.42 $ |
| Cash Flow (TTM) |
5.5 $ |
| Cash |
6.76 $
|
| Book Value |
60.54 $ |
| Dividend (TTM) |
2.9 $ |
|
|
| |
| DIS business |
|
 97.55 % |
of total Revenue |
| All other segments |
|
2.45 % |
of total Revenue |
|
|
1.91%